Fig. 4

The results of MD simulations on 6a-VEGFR2 and sorafenib-VEGFR2 complexes. A. RMSD values of 6a-VEGFR2 and sorafenib-VEGFR2 complexes and 6a and sorafenib ligands during 0.5 ns equilibration and 50 ns production MD simulations. B. The total potential energy of 6a-VEGFR2 and sorafenib-VEGFR2 complexes during the MD simulation